HepaLife Announces Appointment of Dr. Christopher W. Kemp, Vice President of Research...

HepaLife Announces Appointment of Dr. Christopher W. Kemp, Vice President of Research & Development

Successful Biologics Entrepreneur and Researcher Joins HepaLife;
Brings Three Decades of Experience with Cell Biology, Bioreactors, and
Vaccines -- Key to Development of HepaLife's Novel, Cell-Based
Technologies
BOSTON--(Business Wire)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625),
developer of the first-of-its-kind artificial liver device, today
announced the appointment of its Vice President, Research &
Development, Dr. Christopher W. Kemp, a proven cell biology research
scientist and successful entrepreneur with over thirty years of
experience.

During his 17-year tenure as a cell biology researcher, Dr. Kemp
served in various capacities, including a decade of award-winning
service at the National Institutes of Health where he received four
awards for his contribution. Ultimately, Dr. Christopher W. Kemp
founded and operated his own privately-held cell biologics research
firm for 15 years, which was successfully acquired in 2006 by a life
sciences research group with $100 million in equity funding
commitments.

"Chris brings us a unique set of skills, where in addition to his
keen business sense he is an expert in cell-culture process
development and documentation, bioreactor design and operation, and
serum-free medium development. Dr. Kemp's particular know-how of
bioreactors, cells, and process development, directly contributes to
the ongoing development of our entire spectrum of cell-based
technologies," explained Mr. Frank Menzler, President and CEO of
HepaLife.

Effective February 1, 2008, Dr. Kemp will be responsible for
HepaLife's global research efforts and will play a key role in
developing technology strategy plans for the Company's portfolio of
cell-based technologies, including: the first-of-its kind artificial
liver device, in-vitro toxicology testing platforms, and a novel
vaccine production system.

"I am excited to join HepaLife's team of dedicated professionals,
and to support the Company's mission to develop a bioartificial liver
device, potentially helping thousands of patients suffering from liver
disease worldwide," stated Dr. Christopher W. Kemp. "HepaLife has an
excellent array of technologies, and I look forward to implementing
and leading scientific best practices in order to support the
development and growth of our company."

"Chris brings extensive scientific, operational and business
experience to HepaLife. We very much look forward to his contribution
as Vice President of Research and Development," concluded Mr. Menzler.

Christopher W. Kemp, Ph.D.:

Dr. Christopher W. Kemp has over thirty years of experience in the
development of cellular based processes. For the past fifteen years
Dr. Kemp has served as President of Kemp Biotechnologies, Inc., a
private contract manufacturing organization servicing the
pharmaceutical research market.

Dr. Kemp founded Kemp Biotechnologies, Inc. in 1992, subsequently
acquired in 2006 by Pelican Life Sciences, a life sciences research
company backed by $100 million in equity capital commitments. Kemp
Biotechnologies specialized in the scale-up of cellular based
expression systems using novel bioreactor technologies.

Prior to 1992, Dr. Christopher W. Kemp developed serum-free animal
cell culture media formulation for BioWhittaker, Inc. for seven years,
and previously at the National Institutes of Health in Bethesda, MD
worked on process development applications for the production of human
vaccines, where he received four awards during his decade-long tenure.

Dr. Christopher W. Kemp earned his Bachelor of Science degree in
Microbiology from University of Maryland (College Park, MD), and a
Master of Science degree in Biomedical Science from Hood College
(Frederick Park, MD). He completed his Ph.D. in Microbiology at George
Washington University (Washington, D.C.).

ABOUT HEPALIFE TECHNOLOGIES, INC.

Based in Boston, Massachusetts, HepaLife Technologies, Inc.
(OTCBB: HPLF) (FWB: HL1) (WKN: 500625) is a developer of cell-based
medical technologies addressing prevalent human health concerns.

Current cell-based technologies under development by HepaLife
include 1) the first-of-its-kind artificial liver device, 2)
proprietary in-vitro toxicology and pre-clinical drug testing
platforms, and 3) novel cell-culture based vaccine production methods
for the manufacture of vaccines against H5N1 avian influenza and other
viruses.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:

http://www.hepalife.com/investor_alerts.php

To view the full HTML text of this release, please visit:

http://hepalife.com/press_releases/20080122-1.html.php

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a
solicitation of an offer for the purchase or sale of any securities.
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although the Company believes that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have
been correct. Forward-looking statements, which involve assumptions
and describe our future plans, strategies, and expectations, are
generally identifiable by use of the words "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend," or
"project" or the negative of these words or other variations on these
words or comparable terminology. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to adverse economic conditions, intense
competition, lack of meaningful research results, entry of new
competitors and products, adverse federal, state and local government
regulation, inadequate capital, unexpected costs and operating
deficits, increases in general and administrative costs, termination
of contracts or agreements, technological obsolescence of the
Company's products, technical problems with the Company's research and
products, price increases for supplies and components, litigation and
administrative proceedings involving the Company, the possible
acquisition of new businesses or technologies that result in operating
losses or that do not perform as anticipated, unanticipated losses,
the possible fluctuation and volatility of the Company's operating
results, financial condition and stock price, losses incurred in
litigating and settling cases, dilution in the Company's ownership of
its business, adverse publicity and news coverage, inability to carry
out research, development and commercialization plans, loss or
retirement of key executives and research scientists, changes in
interest rates, inflationary factors, and other specific risks. We
currently have no commercial products intended to diagnose, treat,
prevent or cure any disease. The statements contained in this press
release regarding our on going research and development and the
results attained by us to-date have not been evaluated by the Food and
Drug Administration. There can be no assurance that further research
and development, and /or whether clinical trial results, if any, will
validate and support the results of our preliminary research and
studies. Further, there can be no assurance that the necessary
regulatory approvals will be obtained or that HepaLife will be able to
develop commercially viable products on the basis of its technologies.
In addition, other factors that could cause actual results to differ
materially are discussed in the Company's most recent Form 10-Q and
Form 10-K filings with the Securities and Exchange Commission. These
reports and filings may be inspected and copied at the Public
Reference Room maintained by the U.S. Securities & Exchange Commission
at 100 F Street, N.E., Washington, D.C. 20549. You can obtain
information about operation of the Public Reference Room by calling
the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S.
Securities & Exchange Commission also maintains an Internet site that
contains reports, proxy and information statements, and other
information regarding issuers that file electronically with the U.S.
Securities & Exchange Commission at http://www.sec.gov. The Company
undertakes no obligation to publicly release the results of any
revisions to these forward looking statements that may be made to
reflect the events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

HepaLife Technologies, Inc.
Mr. Frank Menzler, President, 800-518-4879

Copyright Business Wire 2008